Cargando…

Effects of erythromycin on voriconazole pharmacokinetics and association with CYP2C19 polymorphism

PURPOSE: To assess the impacts of erythromycin on the pharmacokinetics of voriconazole and its association with CYP2C19 genotypes in healthy Chinese male subjects. METHODS: A single-center, open, crossover clinical study with two treatment phases was carried out. Eighteen healthy male volunteers, in...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shi, Hui-Yan, Yan, Jin, Zhu, Wen-Hui, Yang, Guo-Ping, Tan, Zhi-Rong, Wu, Wei-Hua, Zhou, Gan, Chen, Xiao-Ping, Ouyang, Dong-Sheng
Formato:	Texto
Lenguaje:	English
Publicado:	Springer-Verlag 2010
Materias:	Pharmacokinetics and Disposition
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2957581/ https://www.ncbi.nlm.nih.gov/pubmed/20669013 http://dx.doi.org/10.1007/s00228-010-0869-3

Ejemplares similares

Physiologically based pharmacokinetic modelling to predict the clinical effect of CYP3A inhibitors/inducers on esaxerenone pharmacokinetics in healthy subjects and subjects with hepatic impairment
por: Watanabe, Akiko, et al.
Publicado: (2021)

Ethnicity evaluation of ferric pyrophosphate citrate among Asian and Non-Asian populations: a population pharmacokinetics analysis
por: Zhang, Lingxiao, et al.
Publicado: (2022)

Pharmacokinetics of gemcitabine in non-small-cell lung cancer patients: impact of the 79A>C cytidine deaminase polymorphism
por: Maring, Jan Gerard, et al.
Publicado: (2010)

Evaluation of CYP2C19 activity using microdosed oral omeprazole in humans
por: Elbe, Annika, et al.
Publicado: (2022)

Tolerability and pharmacokinetics of non-fixed and fixed combinations of artesunate and amodiaquine in Malaysian healthy normal volunteers
por: Navaratnam, Visweswaran, et al.
Publicado: (2009)

Effects of cytochrome P450 (CYP3A4 and CYP2C19) inhibition and induction on the exposure of selumetinib, a MEK1/2 inhibitor, in healthy subjects: results from two clinical trials
por: Dymond, Angela W., et al.
Publicado: (2016)

Application of physiologically based pharmacokinetic modeling to predict the pharmacokinetics of telavancin in obesity with renal impairment
por: Wu, Wanhong, et al.
Publicado: (2021)

Population-based meta-analysis of chloroquine: informing chloroquine pharmacokinetics in COVID-19 patients
por: Yao, Xueting, et al.
Publicado: (2020)

Effect of hepatic or renal impairment on the pharmacokinetics of evacetrapib
por: Small, David S., et al.
Publicado: (2016)

Population pharmacokinetics of cefotaxime in intensive care patients
por: Swartling, Maria, et al.
Publicado: (2021)

Population pharmacokinetic analysis of infliximab in patients with ulcerative colitis
por: Fasanmade, Adedigbo A., et al.
Publicado: (2009)

Plasma pharmacokinetics and synovial concentrations of S-flurbiprofen plaster in humans
por: Yataba, Ikuko, et al.
Publicado: (2015)

Population pharmacokinetics of haloperidol in terminally ill adult patients
por: Franken, L. G., et al.
Publicado: (2017)

Population pharmacokinetics of lopinavir/ritonavir in Covid-19 patients
por: Alvarez, Jean Claude, et al.
Publicado: (2020)

Pharmacokinetics and tolerability of artesunate and amodiaquine alone and in combination in healthy volunteers
por: Orrell, Catherine, et al.
Publicado: (2008)

A clinically relevant pharmacokinetic interaction between cyclosporine and imatinib
por: Atiq, Ferdows, et al.
Publicado: (2016)

Population pharmacokinetics and target attainment of ciprofloxacin in critically ill patients
por: Abdulla, Alan, et al.
Publicado: (2020)

Body composition is associated with tacrolimus pharmacokinetics in kidney transplant recipients
por: Francke, M. I., et al.
Publicado: (2022)

Pharmacokinetics and pharmacodynamics of moist inhalation epinephrine using a mobile inhaler
por: Breuer, C., et al.
Publicado: (2013)

Pharmacokinetics of intravenous telavancin in healthy subjects with varying degrees of renal impairment
por: Worboys, Philip D., et al.
Publicado: (2015)

Pharmacokinetics and pharmacodynamics of ticagrelor in subjects on hemodialysis and subjects with normal renal function
por: Teng, Renli, et al.
Publicado: (2018)

A population pharmacokinetic model for simvastatin and its metabolites in children and adolescents
por: Ogungbenro, Kayode, et al.
Publicado: (2019)

Normal fat mass cannot be reliably estimated in typical pharmacokinetic studies
por: Wasmann, Roeland E., et al.
Publicado: (2020)

The effect of dipyridamole on the pharmacokinetics of metformin: a randomized crossover study in healthy volunteers
por: El Messaoudi, S., et al.
Publicado: (2016)

Population pharmacokinetics of levodopa/carbidopa microtablets in healthy subjects and Parkinson’s disease patients
por: Senek, Marina, et al.
Publicado: (2018)

Brivaracetam population pharmacokinetics in children with epilepsy aged 1 month to 16 years
por: Schoemaker, Rik, et al.
Publicado: (2017)

Single dose epidural hydromorphone in labour pain: maternal pharmacokinetics and neonatal exposure
por: Puhto, Terhi, et al.
Publicado: (2020)

Optimal sampling strategies for darunavir and external validation of the underlying population pharmacokinetic model
por: Stillemans, Gabriel, et al.
Publicado: (2020)

The pharmacokinetic interaction between nasally administered naloxone and the opioid remifentanil in human volunteers
por: Tylleskar, Ida, et al.
Publicado: (2021)

Predictive performance of parent-metabolite population pharmacokinetic models of (S)-ketamine in healthy volunteers
por: Otto, M. E., et al.
Publicado: (2021)

Pharmacokinetics of doripenem in plasma and epithelial lining fluid (ELF): comparison of two dosage regimens
por: Oesterreicher, Zoe, et al.
Publicado: (2017)

Levodopa/carbidopa microtablets in Parkinson’s disease: a study of pharmacokinetics and blinded motor assessment
por: Senek, Marina, et al.
Publicado: (2017)

In silico comparison of pharmacokinetic properties of three extended half-life factor IX concentrates
por: Preijers, Tim, et al.
Publicado: (2021)

Influences on the pharmacokinetics of oxycodone: a multicentre cross-sectional study in 439 adult cancer patients
por: Andreassen, Trine Naalsund, et al.
Publicado: (2010)

Treatment with subcutaneous and transdermal fentanyl: results from a population pharmacokinetic study in cancer patients
por: Oosten, Astrid W., et al.
Publicado: (2016)

Single-dose pharmacokinetics and safety of azilsartan medoxomil in children and adolescents with hypertension as compared to healthy adults
por: Webb, Nicholas J. A., et al.
Publicado: (2016)

Influence of genetic co-factors on the population pharmacokinetic model for clopidogrel and its active thiol metabolite
por: Danielak, Dorota, et al.
Publicado: (2017)

Population pharmacokinetic modelling to quantify the magnitude of drug-drug interactions between amlodipine and antiretroviral drugs
por: Courlet, Perrine, et al.
Publicado: (2021)

VKORC1-dependent pharmacokinetics of intravenous and oral phylloquinone (vitamin K1) mixed micelles formulation
por: Marinova, Milka, et al.
Publicado: (2012)

Applying pharmacokinetic/pharmacodynamic measurements for linezolid in critically ill patients: optimizing efficacy and reducing resistance occurrence
por: El-Gaml, Rasha M., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_5bbjqelodof415cg6ee60v2mrn